NCI NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprisesNew NOFO aims to shrink applications by 40% October 30, 2026Vol.52 No.40By Paul Goldberg
NCI NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts“We could do a lot more than be another committee to check the RFAs before they go to the next level.” October 30, 2026Vol.52 No.40By Jacquelyn Cobb
In Brief Dinah Singer retires from NCI, remains at NIH as Scientist Emeritus October 30, 2026Vol.52 No.40
In Brief University of Illinois’ Andrei Gartel receives NCI grant to study AML October 30, 2026Vol.52 No.40
In Brief OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma October 23, 2026Vol.52 No.39
Cancer Policy Letai announces: NCI met FY26 goal of full funding payout October 16, 2026Vol.52 No.38By Claire Marie Porter
Podcast As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns” October 14, 2026
Podcast Anthony Letai reflects on Year One as NCI Director: “The NCI is in business” October 07, 2026
Conversation with The Cancer Letter With Year One metrics in hand, Letai is ready to “bring it home” in Year Two“I hope I don’t see any more reports of NCI cutting funding, because it just is not consistent with the facts” October 02, 2026Vol.52 No.36By Paul Goldberg
PodcastThe Directors The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want itLucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish September 25, 2026Vol.52 No.35By Claire Marie Porter and Paul Goldberg
